Hasil Pencarian - Jorge Gomez‐Miragaya

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer

    Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer oleh Jorge Gomez-Miragaya, Eva González-Suárez

    Diterbitkan 2017-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.

    Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. oleh Adriana Blancafort, Ariadna Giró-Perafita, Glòria Oliveras, Sònia Palomeras, Carlos Turrado, Òscar Campuzano, Dolors Carrión-Salip, Anna Massaguer, Ramon Brugada, Marta Palafox, Jorge Gómez-Miragaya, Eva González-Suárez, Teresa Puig

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

    Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population oleh Jorge Gómez-Miragaya, Marta Palafox, Laia Paré, Guillermo Yoldi, Irene Ferrer, Sergi Vila, Patricia Galván, Pasquale Pellegrini, Hector Pérez-Montoyo, Ana Igea, Purificación Muñoz, Manel Esteller, Angel R. Nebreda, Ander Urruticoechea, Idoia Morilla, Sonia Pernas, Fina Climent, María Teresa Soler-Monso, Ana Petit, Violeta Serra, Aleix Prat, Eva González-Suárez

    Diterbitkan 2017-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer

    RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer oleh Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A. Rakha, Andrew R. Green, Patricia G. Santamaria, Celine Mulder, Simone Lemeer, Joaquin Arribas, Aleix Prat, Teresa Puig, Eva Gonzalez-Suarez

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer

    RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer oleh Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: